295 related articles for article (PubMed ID: 31102159)
41. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature.
Batóg P; Rencz F; Péntek M; Gulácsi L; Filipiak KJ; Prevolnik Rupel V; Simon J; Brodszky V; Baji P; Závada J; Petrova G; Rotar A; Golicki D
Kardiol Pol; 2018; 76(5):860-870. PubMed ID: 29350378
[TBL] [Abstract][Full Text] [Related]
42. Health inequity assessment in Brazil: is EQ-5D-3L sensible enough to detect differences among distinct socioeconomic groups?
Tura BR; da Costa MR; Lordello S; Barros D; Souza Y; da Silva Santos M
Health Qual Life Outcomes; 2024 Feb; 22(1):22. PubMed ID: 38409033
[TBL] [Abstract][Full Text] [Related]
43. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
44. EQ-5D-3L health status and health state utilities of the oldest-old (85 +) in Germany: results from the AgeCoDe-AgeQualiDe study.
König HH; Brettschneider C; Lühmann D; Kaduszkiewicz H; Oey A; Wiese B; Werle J; Weyerer S; Fuchs A; Pentzek M; Conrad I; Röhr S; Weeg D; Bickel H; Heser K; Wagner M; Scherer M; Maier W; Riedel-Heller SG; Hajek A
Qual Life Res; 2020 Dec; 29(12):3223-3232. PubMed ID: 32851600
[TBL] [Abstract][Full Text] [Related]
45. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
Kiadaliri AA; Eliasson B; Gerdtham UG
Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
[TBL] [Abstract][Full Text] [Related]
46. Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys.
Martí-Pastor M; Pont A; Ávila M; Garin O; Vilagut G; Forero CG; Pardo Y; Tresserras R; Medina-Bustos A; Garcia-Codina O; Cabasés J; Rajmil L; Alonso J; Ferrer M
Popul Health Metr; 2018 Aug; 16(1):14. PubMed ID: 30115092
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
48. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
49. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
50. Acceptable health and ageing: results of a cross-sectional study from Hungary.
Péntek M; van Exel J; Gulácsi L; Brodszky V; Zrubka Z; Baji P; Rencz F; Brouwer WBF
Health Qual Life Outcomes; 2020 Oct; 18(1):346. PubMed ID: 33081803
[TBL] [Abstract][Full Text] [Related]
51. [Health status of the Hungarian population between 2000-2010].
Baji P; Brodszky V; Rencz F; Boncz I; Gulácsi L; Péntek M
Orv Hetil; 2015 Dec; 156(50):2035-44. PubMed ID: 26639645
[TBL] [Abstract][Full Text] [Related]
52. Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology.
Hermann Z; Péntek M; Gulácsi L; Kopcsóné Németh IA; Zrubka Z
Eur J Health Econ; 2022 Sep; 23(7):1243-1255. PubMed ID: 34985585
[TBL] [Abstract][Full Text] [Related]
53. Experience-based VAS values for EQ-5D-3L health states in a national general population health survey in China.
Sun S; Chen J; Kind P; Xu L; Zhang Y; Burström K
Qual Life Res; 2015 Mar; 24(3):693-703. PubMed ID: 25246184
[TBL] [Abstract][Full Text] [Related]
54. Valuation of EQ-5D-3l Health States in Slovenia: VAS Based and TTO Based Value Sets.
Prevolnik Rupel V; Srakar A; Rand K
Zdr Varst; 2020 Mar; 59(1):8-17. PubMed ID: 32952698
[TBL] [Abstract][Full Text] [Related]
55. Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study.
Golicki D; Niewada M; Jakubczyk M; Wrona W; Hermanowski T
Pol Arch Med Wewn; 2010 Jul; 120(7-8):276-81. PubMed ID: 20693958
[TBL] [Abstract][Full Text] [Related]
56. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
57. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
58. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
Stevens K; Brazier J; Rowen D
Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
[TBL] [Abstract][Full Text] [Related]
59. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
[TBL] [Abstract][Full Text] [Related]
60. Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L.
Mangen MJ; Bolkenbaas M; Huijts SM; van Werkhoven CH; Bonten MJ; de Wit GA
Health Qual Life Outcomes; 2017 Jan; 15(1):3. PubMed ID: 28069062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
